Browse by author
Lookup NU author(s): Professor David Burn
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Background: The antiepileptic drug topiramate reduces levodopa-induced dyskinesia without exacerbating parkinsonism in animal models. We report a randomized, double-blind, placebo-controlled crossover trial in patients with Parkinson's disease and levodopa-induced dyskinesia.Methods: Fifteen patients with Parkinson's disease and stable levodopa-induced dyskinesia were enrolled into the study, of whom 13 were randomized to topiramate or placebo. The study medication was titrated to 100 mg/day over four weeks, and assessments were carried out after a further two weeks. Dyskinesia severity assessed by a blinded rater from video recordings was the primary outcome measure.Results: Seven patients (mean age 58.9 +/- 12.8 years) completed the study. Patients taking topiramate vs. placebo showed a significant increase in dyskinesia severity compared to baseline (Wilcoxon signed rank test, P = 0.043). Five patients withdrew from the study whilst taking topiramate due to adverse effects.Conclusions: Topiramate tended to worsen dyskinesia in patients with Parkinson's disease, and was poorly tolerated. (C) 2014 Elsevier Ltd. All rights reserved.
Author(s): Kobylecki C, Burn DJ, Kass-Iliyya L, Kellett MW, Crossman AR, Silverdale MA
Publication type: Article
Publication status: Published
Journal: Parkinsonism & Related Disorders
Print publication date: 28/01/2014
ISSN (print): 1353-8020
ISSN (electronic): 1873-5126
Altmetrics provided by Altmetric